ClinicalTrials.gg
Status unknownNCT03825705Updated Oct 31, 2019

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

A Phase 1/2 interventional study of TQB2450 injection and Anlotinib in Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-31.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing anlotinib in Carcinoma, Hepatocellular — 5 open to participants now, 6 under way, 2 of them phase 3. anlotinib · Carcinoma, Hepatocellular.

Planned enrollment
5th of 19
60 · median 37
Started
2019
with 5 others
Phase 1/2
2 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
5 of 19
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 19 studies testing anlotinib in Carcinoma, Hepatocellular, this one is the 5th largest by planned enrollment, is one of 6 that started in 2019, is one of 2 in phase 1/2, and was the 2nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 19 studies testing anlotinib in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing anlotinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma

03

Conditions studied

  • Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Over 18 years old; physical condition: 0 - 1 points; expected survival time more than 3 months; 2、 or pathologically confirmed patients with unresectable or cholangiocarcinoma, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC) and gallbladder cancer (GBC), or advanced hepatocellular carcinoma (Barcelona hepatocellular carcinoma stage C, or unsuitable for stage B patients who failed to receive or receive local treatment); 3、Patients had at least one ( 1.1); 4、Previous chemotherapy failed in patients with adenocarcinoma of the biliary system. First-line chemotherapy failure is defined as disease progression during or after the last treatment, or intolerable side effects during treatment. (Note: a. The first-line treatment time is more than one cycle of combined chemotherapy drugs; B. or adjuvant chemotherapy is allowed in the early stage. If disease progression/recurrence occurs during neoadjuvant/adjuvant therapy or within 6 months after the end of treatment, neoadjuvant/adjuvant therapy is considered to be the first-line systemic chemotherapy failure for progressive diseases; C. Previous first-line standardized therapy does not include small molecular inhibitors of angiogenesis or monoclonal antibodies or drugs related to tumor immunity; Patients with hepatocellular carcinoma have not received systemic chemotherapy, molecular targeted drug therapy and immunotherapy; 5、Laboratory tests should be satisfied: routine blood tests: (Hb) > 80g/L (no blood transfusion within 14 days); (ANC) > 1.5 *109/L; (PLT) > 75 *109/L; biochemical tests: (ALT) and glutamic oxaloacetate aminotransferase (AST) = 2.5 * (liver metastasis of tumors, \< 5 *ULN); serum total (TBIL) = 2 *ULN (Gil) Patients with Bert syndrome, \< 3 *ULN; serum creatinine (Cr) = 1.5 *ULN and rate > 50 umol/L; coagulation function: (APTT), international standardized ratio (INR), prothrombin time (PT) = 1.5 *ULN; Doppler ultrasound evaluation: (LVEF) > 50%; Liver Function Rating for Patients with Liver Cancer: A-B (\< 8 points), (Child-Pugh Albumin Rating must be less than 2 points, i.e. more than 28g/L; Bilirubin Rating 1 point, TBIL \< 2.0xULN; Ascites Rating \< 2 points; Hepatic Encephalopathy \< 1 point; Prothrombin Time Rating \< 2 points); 6、Women should agree to use measures (such as intrauterine device [IUD], contraceptive pill or condom) within 6 months of the study period and the end of the study period; serum or urine pregnancy tests are negative within 7 days before the study group and must be non-breastfeeding patients; men should agree to use contraceptive measures during the study period and within 6 months after the end of the study period; 7、The patients voluntarily joined the study and signed the with good compliance.

Exclusion criteria

Exclusion Criteria:

  1. Patients who had previously received treatment with target inhibitors of vascular endothelial growth factor R, including Anlotinib hydrochloride capsules, or other /PD-L1/CTLA-4 antibodies or other immunotherapy against PD-1/PD-L1/CTLA-4 were treated; 2、Severe was observed after administration of other monoclonal antibodies; 3、Within five years, the subjects had other malignant tumors (except cured basal cell carcinoma of skin, carcinoma in situ of prostate and carcinoma in situ of cervix); 4、There is any active disease or history of autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; asthma patients who need bronchiectasis for medical intervention can not be included); but the following patients are allowed to enter the group: vitiligo without systemic treatment, psoriasis, alopecia, well-controlled I. In type 2 diabetes mellitus, hypothyroidism with normal thyroid function is treated by substitution therapy; 5、 therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10mg/prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration; 6、Those with multiple factors affecting oral medication, such as inability to swallow, Post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc; 7、Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage; 8、Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to 3 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, gastric and duodenal active ulcers, ulcerative colitis, or unresected tumors have active bleeding, or may be caused as determined by the researchers. Other conditions of gastrointestinal bleeding and perforation;9、 were detected by CT or MRI at screening, and there was a history of organ transplantation;10、Within four weeks before the start of the study, the patients received approved or in-progress antineoplastic therapy, including but not limited to chemotherapy, surgery, radiotherapy, biological targeted therapy, interventional therapy, immunotherapy and antineoplastic traditional Chinese medicine treatment (based on indications of Chinese medicine instructions, such as 2-week elution period can also be included in the group), etc. (Note: Oral targeting drugs with less than 5 half-lives or oral fluorouracil; Patients with pyridine drugs for less than 14 days, mitomycin C and nitrosourea for less than 6 weeks, and patients whose adverse events (except hair loss) caused by previous treatment did not recover to \< CTCAE 1 degree;11、Patients with any serious and/or uncontrollable disease, including:(a) Patients with unsatisfactory blood pressure control (systolic blood pressure (> 150 mmHg), diastolic blood pressure (> 90 mmHg);(b) Thrombotic events, ischemic attacks, myocardial infarction, grade 2 congestive heart failure or arrhythmias requiring treatment (including (> 480ms) occurred within 6 months of first administration;(C) Severe active or uncontrolled infections (> CTC AE 2 infection), tuberculosis patients;(D) Known clinical history of liver diseases, including viral hepatitis, known carriers of virus (HBV) must exclude active HBV infection, that is, HBV DNA positive (> 1 *104 copies/mL or > 2000 IU/mL); known virus infection (HCV) and HCV RNA positive (> 1 *103 copies/mL), or other decompensated hepatitis and chronic hepatitis, which require antiviral treatment. Therapy;(E) positive;(F) poor control of diabetes mellitus (fasting blood sugar (> CTCAE 2);(G) Urinary routine indicated that urinary protein (++) and confirmed 24-hour urinary protein quantification (>1.0 g);12、Vaccinated with vaccines or attenuated vaccines within 4 weeks after first administration; 13、According to the judgement of the researchers, there are other factors that may lead to the termination of the study. For example, other serious diseases (including mental disorders) need to be treated together, there are serious abnormal laboratory examinations, accompanied by family or social factors, which will affect the safety of the subjects, or the collection of data and samples.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Anlotinib + TQB2450

    TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

    Drug: TQB2450 injection · Drug: Anlotinib

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • A multi-target receptor tyrosine kinase inhibitor

06

What researchers measure

Primary outcomes

  1. Overall Response Rate(ORR)

    Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by RECIST1.1/irRECIST

    Time frame: Up to 96 weeks

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Recruiting
    • Aiping Zhou · Contactzhouap1825@126.com · 010-87788800
    • Aiping Zhou · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Jan 2021, 20 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 20 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2019
First posted
Jan 31, 2019
StartActual
Apr 23, 2019
Primary completionEst.
Jan 1, 2021
CompletionEst.
Jan 1, 2021
Last update
Oct 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03825705
Responsible party
Sponsor
First posted
Jan 31, 2019
Start date
Apr 23, 2019
Primary completion
Jan 1, 2021 (estimated)
Completion
Jan 1, 2021 (estimated)
Last update
Oct 31, 2019

Study contacts

Aiping Zhou
Contact
zhouap1825@126.com
010-87788800

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib

Start the discussion